Format

Send to

Choose Destination
Transfus Apher Sci. 2011 Oct;45(2):175-81. doi: 10.1016/j.transci.2011.07.013. Epub 2011 Aug 15.

Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.

Author information

1
Blood Transfusion Center, Swiss Red Cross, Basel, Switzerland. infantil@uhbs.ch

Abstract

INTRODUCTION:

INTERCEPT treatment is used to reduce platelet transfusion associated bacterial infections. Limited data are available in Switzerland.

PATIENTS AND METHODS:

Patients with thrombocytopenia or thrombocyte dysfunction requiring platelet transfusions were enrolled in a prospective cohort study on safety (primary endpoint) and efficacy (secondary endpoint) of INTERCEPT treated platelets (I-PLTs). I-PLTs were produced from double-dose apheresis products. Data on safety were actively recorded for each transfusion.

RESULTS:

A total of 551 I-PLT units (mean platelet dose: 2.6 ± 0.4 × 10(11)/unit) were transfused to 46 patients (mean number of platelet transfusions per patient: 12 ± 12.5). Fifty-one (9%) transfusions were associated with adverse events and 12 (2%) with acute transfusion reactions. Eleven serious adverse events were observed, none considered as related to the administration of I-PLT. Mean 1-4h and 16-24h CCIs were 10.1 ± 8.1 and 3.6 ± 6.6, respectively.

CONCLUSION:

The transfusion of I-PLT was associated with a good safety profile and adequate platelet count increments at 1-4h.

PMID:
21840762
DOI:
10.1016/j.transci.2011.07.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center